Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial
Why the study?
Does the treatment effect of rivaroxaban versus warfarin for stroke prevention vary based on the trial center's time in therapeutic range (cTTR)?
Population
Patients from the ROCKET AF trial evaluated for stroke prevention
Comparison
Rivaroxaban vs Warfarin
Design
RCT, null, null
Follow-up
null
Authors
Discussion
Loading...
Member takes
Implication
Rivaroxaban's benefit versus warfarin for stroke prevention holds across center TTR levels; confirms consistent efficacy independent of local warfarin control.
Structured PICO
Does the treatment effect of rivaroxaban versus warfarin for stroke prevention vary based on the trial center's time in therapeutic range (cTTR)?
P
Population
Patients from the ROCKET AF trial evaluated for stroke prevention (assessed by CHADS2 scores and prior stroke/TIA history)
I
Intervention
Rivaroxaban
C
Comparator
Warfarin (analyzed by trial center time in therapeutic range [cTTR])
O
Outcome
Stroke or non-central nervous system embolismhard clinical
The efficacy of rivaroxaban compared with warfarin for preventing stroke and systemic embolism is consistent regardless of a center's average time in therapeutic range.
Cite This Study
Piccini et al. (2014) studied this question.